Last $0.38 USD
Change Today -0.0069 / -1.78%
Volume 66.7K
EMIS On Other Exchanges
Symbol
Exchange
OTC BB
As of 3:22 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

emisphere technologies inc (EMIS) Snapshot

Open
$0.39
Previous Close
$0.39
Day High
$0.39
Day Low
$0.37
52 Week High
07/3/14 - $0.46
52 Week Low
12/23/13 - $0.12
Market Cap
23.1M
Average Volume 10 Days
125.5K
EPS TTM
$-0.27
Shares Outstanding
60.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EMISPHERE TECHNOLOGIES INC (EMIS)

emisphere technologies inc (EMIS) Related Bloomberg News

View More Bloomberg News

emisphere technologies inc (EMIS) Related Businessweek News

No Related Businessweek News Found

emisphere technologies inc (EMIS) Details

Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its Eligen technology. Its technology could be applied to the oral route of administration, as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Eligen B12, a medical food for use by B12 deficient individuals; and GLP-1 (glucagon-like peptide-1), which is in Phase II clinical trial for the treatment for Type 2 diabetes. Its preclinical programs focus on the development of oral formulations for the treatment of diabetes; the areas of cardiovascular, appetite suppression, and pain; and the development and expansion of nutritional supplement products. The company has license agreements with Novo Nordisk A/S to develop and commercialize GLP-1 receptor agonists, as well as to develop and commercialize oral formulations of Novo Nordisk’s insulin using the company’s Eligen Technology. It also has a strategic alliance with AAIPharma, Inc. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is headquartered in Roseland, New Jersey.

11 Employees
Last Reported Date: 03/31/14
Founded in 1986

emisphere technologies inc (EMIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $691.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $372.7K
Vice President of Sales & Marketing
Total Annual Compensation: $398.7K
Compensation as of Fiscal Year 2013.

emisphere technologies inc (EMIS) Key Developments

Emisphere Technologies, Inc. Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12

Emisphere Technologies, Inc. announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds (MHR), to finance the upcoming launch of the company's first commercial prescription product, oral Eligen(R) B12 in the United States through a new loan facility, and to amend the terms of the company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes. Under the terms of the new loan facility, Emisphere may borrow, at specified times and based on the attainment of specified performance milestones, up to an aggregate of $20 million to finance the development, manufacturing, marketing and sales of the B12 Product. The new loan facility will mature on December 31, 2019 and bear interest at a rate of 13% per year. The company and MHR also entered into a royalty agreement in connection with the entry into the new loan facility which obligates the company to make certain payments to MHR based on the sale and licensing of Eligen(R) B12 and related products.

Emisphere Technologies, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Emisphere Technologies, Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $8.1 million, or $0.13 per basic and diluted share, compared to a net loss of $14.0 million, or $0.23 per basic and diluted share for the quarter ended June 30, 2013. The company reported an operating loss of $1.5 million for the second quarter 2014, compared to an operating loss of $1.8 million for the same period in 2013. Loss before income tax benefit was $8.069 million against $13.982 million a year ago. The company reported a net loss of $11.4 million, or $0.19 per basic and diluted share, for the six months ended June 30, 2014, compared to a net loss of $16.4 million, or $0.27 per basic and diluted share, for the six months ended June 30, 2013. An operating loss of $3.9 million was reported for the six months ended June 30, 2014, compared to $3.5 million for the same period last year. Loss before income tax benefit was $13.111 million against $16.406 million a year ago.

Emisphere Technologies, Inc. to Report Q2, 2014 Results on Aug 14, 2014

Emisphere Technologies, Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EMIS:US $0.38 USD -0.0069

EMIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EMIS.
View Industry Companies
 

Industry Analysis

EMIS

Industry Average

Valuation EMIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMISPHERE TECHNOLOGIES INC, please visit www.emisphere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.